Outlook Therapeutics, Inc.
ONS-5010/LYTENAVA
neovascular age-related macular degeneration (nAMD)
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on ONS-5010/LYTENAVA for neovascular age-related macular degeneration (nAMD) is expected Date TBD.
Primary source
· SEC 8-K
verified 14h ago
“When approved, ONS-5010/LYTENAVA will be the first and only FDA-approved ophthalmic formulation of bevacizumab supported by standardized manufacturing, FDA-approved labeling, and robust pharmacovigilance.”